Clinical trial
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or…
NCT00445484 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00445484 |
|---|---|
| Title | Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug |
| Interventions | pneumococcal polyvalent vaccine, lenalidomide |
| Enrollment | 22 |
| Start date | Jan 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | Mar 9, 2007 |
| Last update posted | Aug 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: